At Apobiologix, we understand invention is not the only way to innovate. It's this forward thinking that puts our Research and Development team on the leading edge of biosimilar product development.
Our first 2 products are short- and long-acting G-CSF biosimilars.
We launched Grastofil® (filgrastim), biosimilar to Neupogen in Europe in 2013. In 2015, Apobiologix also launched Grastofil in Canada. The FDA is actively reviewing our applications for both Apobiologix pegfilgrastim, biosimilar to Neulasta® and Apobiologix filgrastim, biosimilar to Neupogen® for use in the United States.
2400 North Commerce Parkway,
Weston, Florida 33326
Neupogen® and Neulasta® are registered trademarks of Amgen Inc.
Procrit® is a registered trademark of Janssen Products, LP.
Herceptin® and Avastin® are registered trademarks of Genentech USA, Inc.
Rituxan® is a registered trademark of Biogen.